Patients with systemic lupus erythematosus and sustained low hydroxychloroquine blood levels may be at significantly ...

Objective This study aimed to compare 25-hydroxyvitamin D (25-(OH)D) levels and peripheral lymphocyte subsets between ...

LUMUS trial did not meet its primary and secondary endpoints in the overall trial population –– Robust responses in the prespecified subgroup ...

Adding obinutuzumab to standard therapy may improve disease control and reduce flares in adults with active systemic lupus erythematosus.

Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage ...

Neuropsychiatric symptoms are common in systemic lupus erythematosus (SLE), typically featuring impaired cognition and ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic ...

Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe ...

Thrombotic microangiopathy (TMA) is a rare, but severe complication of systemic lupus erythematosus and lupus nephritis.

Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population.

We know from listening to people living with SLE that they experience a variety of emotional, physical and socioeconomic burdens that can affect their ability to perform day-to-day activities. 1 In ...

Sept 1 (Reuters) - Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet ...